DK3280728T3 - Alk7:actriib-heteromultimerer og anvendelser deraf - Google Patents

Alk7:actriib-heteromultimerer og anvendelser deraf Download PDF

Info

Publication number: DK3280728T3
Authority: DK; Denmark
Prior art keywords: alk7; applications; actriib heteromultimer; actriib; heteromultimer
Prior art date: 2015-04-06

Application number

DK16777229.2T

Other languages

English (en)

Inventor

John Knopf

Ravindra Kumar

Asya Grinberg

Dianne S Sako

Robert Scott Pearsall

Roselyne Castonguay

Gang Li

Yossi Dagon

Original Assignee

Acceleron Pharma Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2015-04-06

Filing date

2016-04-06

Publication date

2021-03-01

2016-04-06 Application filed by Acceleron Pharma Inc filed Critical Acceleron Pharma Inc

2021-03-01 Application granted granted Critical

2021-03-01 Publication of DK3280728T3 publication Critical patent/DK3280728T3/da

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/45—Transferases (2)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y207/00—Transferases transferring phosphorus-containing groups (2.7)
- C12Y207/11—Protein-serine/threonine kinases (2.7.11)
- C12Y207/1103—Receptor protein serine/threonine kinase (2.7.11.30)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Zoology (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Gastroenterology & Hepatology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Physical Education & Sports Medicine (AREA)
Obesity (AREA)
Cell Biology (AREA)
Biophysics (AREA)
Toxicology (AREA)
Biomedical Technology (AREA)
Orthopedic Medicine & Surgery (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Urology & Nephrology (AREA)
Rheumatology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)

DK16777229.2T 2015-04-06 2016-04-06 Alk7:actriib-heteromultimerer og anvendelser deraf DK3280728T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201562143579P	2015-04-06	2015-04-06
PCT/US2016/026277 WO2016164503A1 (en)	2015-04-06	2016-04-06	Alk7:actriib heteromultimers and uses thereof

Publications (1)

Publication Number	Publication Date
DK3280728T3 true DK3280728T3 (da)	2021-03-01

Family

ID=57072866

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK16777229.2T DK3280728T3 (da)	2015-04-06	2016-04-06	Alk7:actriib-heteromultimerer og anvendelser deraf

Country Status (15)

Country	Link
US (7)	US10227393B2 (da)
EP (5)	EP3889171B1 (da)
JP (3)	JP7037363B2 (da)
KR (2)	KR20180002661A (da)
CN (4)	CN115073610A (da)
AU (4)	AU2016244750B2 (da)
BR (1)	BR112017021510A2 (da)
CA (2)	CA2981737A1 (da)
DK (1)	DK3280728T3 (da)
EA (2)	EA037293B1 (da)
ES (1)	ES2863564T3 (da)
HK (2)	HK1250373A1 (da)
MA (4)	MA54328A (da)
MX (1)	MX391964B (da)
WO (2)	WO2016164089A2 (da)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN105658672A (zh)	2013-08-22	2016-06-08	阿塞勒隆制药公司	TGF-β受体II型变体及其用途
US10588980B2 (en)	2014-06-23	2020-03-17	Novartis Ag	Fatty acids and their use in conjugation to biomolecules
MA41919A (fr)	2015-04-06	2018-02-13	Acceleron Pharma Inc	Hétéromultimères alk4:actriib et leurs utilisations
BR112017021510A2 (pt)	2015-04-06	2018-07-03	Acceleron Pharma Inc	heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
JP6810702B2 (ja)	2015-04-06	2021-01-06	アクセルロンファーマインコーポレイテッド	シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
RS61881B1 (sr)	2015-04-22	2021-06-30	Biogen Ma Inc	Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića
CN116327952A (zh)	2015-08-04	2023-06-27	阿塞勒隆制药公司	用于治疗骨髓增生性病症的方法
CN105254764A (zh) *	2015-08-27	2016-01-20	上海康岱生物医药技术有限公司	ACVR1-Fc融合蛋白及其制法和用途
EP3439741A4 (en)	2016-04-06	2020-05-06	Acceleron Pharma Inc.	ALK7 ANTAGONISTS AND USES THEREOF
AU2017296040C1 (en)	2016-07-15	2023-06-22	Acceleron Pharma Inc.	Compositions and methods for treating pulmonary hypertension
WO2018067874A1 (en)	2016-10-05	2018-04-12	Acceleron Pharma Inc.	Variant actriib proteins and uses thereof
JP2019529509A (ja) *	2016-10-05	2019-10-17	アクセレロンファーマインコーポレーテッド	腎臓疾患を治療するための組成物および方法
EP3522913A4 (en)	2016-10-05	2020-10-28	Acceleron Pharma Inc.	ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES
AU2017338915B2 (en) *	2016-10-05	2024-11-21	Acceleron Pharma Inc.	TGF-beta superfamily type I and type II receptor heteromultimers and uses thereof
JOP20190085A1 (ar)	2016-10-20	2019-04-17	Biogen Ma Inc	طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
EP3538123A4 (en)	2016-11-10	2020-10-14	Keros Therapeutics, Inc.	ACTIVIN RECEPTOR TYPE IIA VARIANTS AND THEIR METHODS OF USE
EP3541833B1 (en) *	2016-11-17	2024-01-24	2seventy bio, Inc.	Tgf beta signal convertor
AU2018214979A1 (en) *	2017-02-01	2019-08-15	Acceleron Pharma Inc.	TGFβ and actrii antagonists for use in increasing immune activity
DK3628049T3 (da)	2017-05-04	2023-08-14	Acceleron Pharma Inc	Tgf-beta-receptortype-ii-fusionsproteiner og anvendelser deraf
EP3424957A1 (en) *	2017-07-03	2019-01-09	advanceCOR GmbH	Fusion protein
WO2019086331A2 (en) *	2017-11-02	2019-05-09	Bayer Aktiengesellschaft	Bispecific antibodies binding alk-1 and bmpr-2
CN120399032A (zh)	2018-01-12	2025-08-01	科乐斯疗法公司	激活素受体iib型变体及其使用方法
EP3749682B1 (en) *	2018-02-09	2025-09-24	Acceleron Pharma Inc.	Treating heterotopic ossification
AU2019231205A1 (en) *	2018-03-06	2020-09-24	The Trustees Of The University Of Pennsylvania	Prostate-specific membrane antigen cars and methods of use thereof
EP3788067A4 (en) *	2018-05-03	2022-01-19	Acceleron Pharma Inc.	NOVEL BINDERS OF TGFBETA SUPERFAMILY LIGANDS AND THEIR USES
JP2021522793A (ja) *	2018-05-03	2021-09-02	アクセルロンファーマインコーポレイテッド	ＴＧＦβスーパーファミリーリガンドの多特異性バインダーおよびその使用
EP3790572A4 (en)	2018-05-09	2022-03-16	Keros Therapeutics, Inc.	ACTIVIN RECEPTOR TYPE IIA VARIANTS AND METHODS OF USE THEREOF
AU2019272575A1 (en)	2018-05-21	2020-12-10	Compass Therapeutics Llc	Compositions and methods for enhancing the killing of target cells by NK cells
WO2019226658A1 (en)	2018-05-21	2019-11-28	Compass Therapeutics Llc	Multispecific antigen-binding compositions and methods of use
EP3807308A4 (en) *	2018-06-15	2022-03-16	Acceleron Pharma Inc.	BI AND TRIFUNCTIONAL FUSION PROTEINS AND THEIR USES
WO2021021528A1 (en) *	2019-07-26	2021-02-04	Board Of Trustees Of Michigan State University	Methods of preventing or treating fatty degeneration of skeletal muscle
CN112625137B (zh) *	2019-10-08	2021-10-08	北京东方百泰生物科技股份有限公司	一种人白细胞介素10-Fc融合蛋白及其医药用途
BR112022015387A2 (pt) *	2020-02-03	2022-10-11	Acceleron Pharma Inc	Proteínas actriib variantes e usos das mesmas
CN115515618A (zh) *	2020-03-13	2022-12-23	阿塞勒隆制药公司	用于治疗肾脏疾病或病症的单臂ActRIIA和ActRIIB异多聚体和方法
EP4121088A4 (en)	2020-03-20	2024-07-03	Keros Therapeutics, Inc.	Methods of using activin receptor type iib variants
AU2021237730A1 (en) *	2020-03-20	2022-10-06	Keros Therapeutics, Inc.	Activin receptor type II chimeras and methods of use thereof
KR102587871B1 (ko) *	2020-06-19	2023-10-12	숙명여자대학교산학협력단	Bmpr2 유전자 기능획득 돌연변이체를 포함하는 돌연변이 복합체 및 이의 용도
EP4240388A4 (en) *	2020-11-04	2024-10-16	HAN, Hq	NOVEL BIFUNCTIONAL MULTISPECIFIC ANTAGONISTS CAPABLE OF INHIBITING MULTIPLE TGF-BETA FAMILY LIGANDS AND USES THEREOF
WO2022192411A1 (en) *	2021-03-10	2022-09-15	Acceleron Pharma Inc.	Actrii-alk4 antagonists and methods of treating heart failure
WO2022192404A1 (en) *	2021-03-10	2022-09-15	Acceleron Pharma Inc.	Actrii-alk4 antagonists and methods of treating heart failure
WO2024182505A1 (en) *	2023-03-01	2024-09-06	The Regents Of The University Of California	Use of bmp receptor alk1 inhibitors in osteoarthritis therapies
WO2025034616A1 (en) *	2023-08-04	2025-02-13	Lask Pharma, Inc.	Soluble bone morphogenetic protein (bmp) receptor type-1b proteins and uses thereof
WO2025137384A1 (en) *	2023-12-20	2025-06-26	Arrowhead Pharmaceuticals, Inc.	Methods and reagents for improved oligonucleotide synthesis

Family Cites Families (111)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5955A (en)		1848-12-05		Plate for boiler-holes in cooking-stoves
DE3382562D1 (de)	1982-09-24	1992-06-25	Us Health	Wiederherstellung von gewebe bei tieren.
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US4676980A (en)	1985-09-23	1987-06-30	The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services	Target specific cross-linked heteroantibodies
US6548640B1 (en)	1986-03-27	2003-04-15	Btg International Limited	Altered antibodies
IL85035A0 (en)	1987-01-08	1988-06-30	Int Genetic Eng	Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5080891A (en)	1987-08-03	1992-01-14	Ddi Pharmaceuticals, Inc.	Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US5223409A (en)	1988-09-02	1993-06-29	Protein Engineering Corp.	Directed evolution of novel binding proteins
WO1990005144A1 (en)	1988-11-11	1990-05-17	Medical Research Council	Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
US5198346A (en)	1989-01-06	1993-03-30	Protein Engineering Corp.	Generation and selection of novel DNA-binding proteins and polypeptides
US5096815A (en)	1989-01-06	1992-03-17	Protein Engineering Corporation	Generation and selection of novel dna-binding proteins and polypeptides
DE3920358A1 (de)	1989-06-22	1991-01-17	Behringwerke Ag	Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en)	1990-01-12	2000-11-21	Abgenix, Inc.	Human antibodies derived from immunized xenomice
US6075181A (en)	1990-01-12	2000-06-13	Abgenix, Inc.	Human antibodies derived from immunized xenomice
KR970002255B1 (ko)	1990-06-11	1997-02-26	넥스스타 파아마슈티컬드, 인크.	핵산 리간드
US5270163A (en)	1990-06-11	1993-12-14	University Research Corporation	Methods for identifying nucleic acid ligands
US5707796A (en)	1990-06-11	1998-01-13	Nexstar Pharmaceuticals, Inc.	Method for selecting nucleic acids on the basis of structure
US5580737A (en)	1990-06-11	1996-12-03	Nexstar Pharmaceuticals, Inc.	High-affinity nucleic acid ligands that discriminate between theophylline and caffeine
US5763177A (en)	1990-06-11	1998-06-09	Nexstar Pharmaceuticals, Inc.	Systematic evolution of ligands by exponential enrichment: photoselection of nucleic acid ligands and solution selex
US5567588A (en)	1990-06-11	1996-10-22	University Research Corporation	Systematic evolution of ligands by exponential enrichment: Solution SELEX
US5770429A (en)	1990-08-29	1998-06-23	Genpharm International, Inc.	Transgenic non-human animals capable of producing heterologous antibodies
WO1992009690A2 (en)	1990-12-03	1992-06-11	Genentech, Inc.	Enrichment method for variant proteins with altered binding properties
US5571894A (en)	1991-02-05	1996-11-05	Ciba-Geigy Corporation	Recombinant antibodies specific for a growth factor receptor
US20050186593A1 (en) *	1991-05-10	2005-08-25	The Salk Institute For Biological Studies	Cloning and recombinant production of CRF receptor(s)
EP0590058B1 (en)	1991-06-14	2003-11-26	Genentech, Inc.	HUMANIZED Heregulin ANTIBODy
GB9114948D0 (en)	1991-07-11	1991-08-28	Pfizer Ltd	Process for preparing sertraline intermediates
FI941572L (fi)	1991-10-07	1994-05-27	Oncologix Inc	Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en)	1991-11-04	1993-05-13	The Regents Of The University Of California	Compositions that mediate killing of hiv-infected cells
US5932448A (en)	1991-11-29	1999-08-03	Protein Design Labs., Inc.	Bispecific antibody heterodimers
ATE419355T1 (de)	1992-02-06	2009-01-15	Novartis Vaccines & Diagnostic	Marker für krebs und biosynthetisches bindeprotein dafür
AU683431B2 (en)	1992-11-17	1997-11-13	Ludwig Institute For Cancer Research	Activin receptor-like kinases, proteins having serine/ threonine kinase domains and their use
US7592428B1 (en)	1992-11-17	2009-09-22	Ludwig Institute For Cancer Research	Antibodies which bind specifically to activin receptor like kinases
US5677196A (en)	1993-05-18	1997-10-14	University Of Utah Research Foundation	Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays
US5525490A (en)	1994-03-29	1996-06-11	Onyx Pharmaceuticals, Inc.	Reverse two-hybrid method
US5614609A (en)	1994-10-20	1997-03-25	Carlos F. Ibanez	Serine threonine kinase receptor
US5814565A (en)	1995-02-23	1998-09-29	University Of Utah Research Foundation	Integrated optic waveguide immunosensor
US5731168A (en)	1995-03-01	1998-03-24	Genentech, Inc.	Method for making heteromultimeric polypeptides
CA2217545A1 (en)	1995-04-11	1996-10-17	Marc Vidal	Reverse two-hybrid systems
US5869046A (en)	1995-04-14	1999-02-09	Genentech, Inc.	Altered polypeptides with increased half-life
US6699843B2 (en)	1995-06-07	2004-03-02	Gilead Sciences, Inc.	Method for treatment of tumors using nucleic acid ligands to PDGF
JPH10303327A (ja)	1997-04-23	1998-11-13	Yamaichi Electron Co Ltd	半導体チップの接点変換構造と該接点変換構造を有する半導体チップの製造法
US20020062010A1 (en)	1997-05-02	2002-05-23	Genentech, Inc.	Method for making multispecific antibodies having heteromultimeric and common components
US6011577A (en)	1997-06-30	2000-01-04	Polaroid Corporation	Modular optical print head assembly
EP1015468A4 (en)	1997-08-29	2000-09-06	Human Genome Sciences Inc	FOLLISTATINE-3
US6610833B1 (en)	1997-11-24	2003-08-26	The Institute For Human Genetics And Biochemistry	Monoclonal human natural antibodies
JP4460155B2 (ja)	1997-12-05	2010-05-12	ザ・スクリプス・リサーチ・インステイチユート	マウス抗体のヒト化
US6335155B1 (en)	1998-06-26	2002-01-01	Sunesis Pharmaceuticals, Inc.	Methods for rapidly identifying small organic molecule ligands for binding to biological target molecules
US6927044B2 (en)	1998-09-25	2005-08-09	Regeneron Pharmaceuticals, Inc.	IL-1 receptor based cytokine traps
JP2002533726A (ja)	1998-12-28	2002-10-08	サネシスファーマシューティカルスインコーポレイテッド	結合のための小有機分子リガンドの同定
US6737056B1 (en)	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
BR0008188A (pt)	1999-01-21	2002-02-13	Metamorphix Inc	Inibidores de fator de diferenciação de crescimento e usos para os mesmos
ATE428719T1 (de)	1999-07-29	2009-05-15	Gilead Sciences Inc	Nukleinsäureliganden für den hepatozytischen wachstumsfaktor/dispersionsfaktor (hgf/sf) und seines c-met rezeptors
US20030180714A1 (en)	1999-12-15	2003-09-25	Genentech, Inc.	Shotgun scanning
DK1272647T3 (da)	2000-04-11	2014-12-15	Genentech Inc	Multivalente antistoffer og anvendelser deraf
US6596541B2 (en)	2000-10-31	2003-07-22	Regeneron Pharmaceuticals, Inc.	Methods of modifying eukaryotic cells
DK1354034T3 (da)	2000-11-30	2008-03-25	Medarex Inc	Transgene transchromosomale gnavere til fremstilling af humane antistoffer
CA2488441C (en)	2002-06-03	2015-01-27	Genentech, Inc.	Synthetic antibody phage libraries
US20040223966A1 (en)	2002-10-25	2004-11-11	Wolfman Neil M.	ActRIIB fusion polypeptides and uses therefor
US20050079574A1 (en)	2003-01-16	2005-04-14	Genentech, Inc.	Synthetic antibody phage libraries
CA2539116C (en)	2003-09-15	2014-11-18	Research Development Foundation	Cripto antagonism of activin and tgf-b signaling
WO2005025601A1 (en)	2003-09-15	2005-03-24	Monash University	Follistatin isoforms and uses thereof
EP1729793B1 (en) *	2004-03-02	2015-07-22	Acceleron Pharma Inc.	Alk7 and myostatin inhibitors for muscle wasting disorders
CA2561686C (en)	2004-03-31	2014-12-02	Genentech, Inc.	Humanized anti-tgf-beta antibodies
US7785903B2 (en)	2004-04-09	2010-08-31	Genentech, Inc.	Variable domain library and uses
BR122019012028B1 (pt)	2004-04-13	2023-09-26	F. Hoffmann-La Roche Ag	Anticorpos anti-p-selectina, molécula de ácido nucléico, vetor, e composição
ES2551852T3 (es)	2004-07-23	2015-11-24	Acceleron Pharma Inc.	Polipéptidos del receptor ActRII
TWI380996B (zh)	2004-09-17	2013-01-01	Hoffmann La Roche	抗ｏｘ４０ｌ抗體
ES2579805T3 (es)	2004-09-23	2016-08-16	Genentech, Inc.	Anticuerpos y conjugados modificados por ingeniería genética con cisteína
EP2465870A1 (en)	2005-11-07	2012-06-20	Genentech, Inc.	Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
EA201692543A1 (ru)	2005-11-23	2017-08-31	Акселерон Фарма Инк.	Антагонисты активина-actriia и их применение для стимулирования роста кости
SI1973559T1 (sl) *	2005-11-23	2013-05-31	Acceleron Pharma, Inc.	Aktivin-aktriia antagonisti in uporaba za pospeĺ evanje kostne rasti
US20070237764A1 (en)	2005-12-02	2007-10-11	Genentech, Inc.	Binding polypeptides with restricted diversity sequences
WO2007134050A2 (en)	2006-05-09	2007-11-22	Genentech, Inc.	Binding polypeptides with optimized scaffolds
AU2007254824A1 (en) *	2006-06-02	2007-12-13	Wyeth	Use of proteins and peptides of the TGF-beta superfamily for purification and therapeutic methods
WO2007147901A1 (en)	2006-06-22	2007-12-27	Novo Nordisk A/S	Production of bispecific antibodies
WO2008030367A2 (en)	2006-09-01	2008-03-13	The General Hospital Corporation	Selective myostatin inhibitors
WO2008057461A2 (en) *	2006-11-02	2008-05-15	Acceleron Pharma, Inc.	Alk1 receptor and ligand antagonists and uses thereof
WO2008073351A2 (en)	2006-12-08	2008-06-19	Acceleron Pharma Inc.	Uses of cerberus, coco and derivatives thereof
EP2468291B1 (en) *	2006-12-18	2017-11-22	Acceleron Pharma, Inc.	Activin-actrii antagonists and uses for increasing red blood cell levels
TWI782836B (zh) *	2007-02-02	2022-11-01	美商艾瑟勒朗法瑪公司	衍生自ActRIIB的變體與其用途
TWI573802B (zh)	2007-03-06	2017-03-11	安美基公司	變異之活動素受體多肽及其用途
US8318135B2 (en)	2007-03-19	2012-11-27	National Research Council Of Canada	Antagonist of ligands and uses thereof
CN100592373C (zh)	2007-05-25	2010-02-24	群康科技(深圳)有限公司	液晶显示面板驱动装置及其驱动方法
PT2235064E (pt)	2008-01-07	2016-03-01	Amgen Inc	Método de preparação de moléculas heterodiméricas de fc de anticorpos utilizando efeitos de indução eletrostática
TWI586364B (zh) *	2008-05-02	2017-06-11	艾西利羅製藥公司	調節血管新生與周圍細胞組成的方法與組合物
JP5922928B2 (ja)	2008-08-14	2016-05-24	アクセルロンファーマ，インコーポレイテッド	赤血球レベルを高めるためのｇｄｆトラップの使用
EP2326670A4 (en)	2008-09-17	2014-04-16	Nat Res Council Canada	HETERO MULTIVALENT BINDING AGENT FOR ELEMENTS OF THE TGF-BETA SUPERFAMILY
ME02652B (me) *	2008-11-26	2017-06-20	Amgen Inc	Stabilizovana varijanta aktivin iib receptora
EP2387412A4 (en)	2009-01-13	2013-04-03	Acceleron Pharma Inc	PROCESS FOR INCREASING THE ADIPONECTIN MIRROR
CN102548617B (zh)	2009-03-30	2017-11-07	阿塞勒隆制药公司	Bmp‑alk3拮抗剂和促进骨生长的用途
EP2440577A4 (en) *	2009-06-12	2013-01-23	Acceleron Pharma Inc	SHORTEN ACTRIIB FC FUSION PROTEINS
CA2781519A1 (en)	2009-09-16	2011-03-24	Genentech, Inc.	Coiled coil and/or tether containing protein complexes and uses thereof
FR2951408B1 (fr)	2009-10-15	2012-01-13	Renault Sa	Cadre moteur pour moteur electrique de vehicule automobile
TWI426920B (zh)	2010-03-26	2014-02-21	Hoffmann La Roche	雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體
WO2012027065A2 (en)	2010-08-27	2012-03-01	Celgene Corporation	Combination therapy for treatment of disease
CN102850458B (zh)	2011-06-28	2014-10-01	华博生物医药技术（上海）有限公司	新型重组双功能融合蛋白及其制法和用途
WO2013063536A1 (en) *	2011-10-27	2013-05-02	Acceleron Pharma, Inc.	Actriib binding agents and uses thereof
SI2831105T1 (en)	2012-03-28	2018-03-30	The Board Of Regents Of The University Of Texas System	FUZIJA TGF TIPA II AND III RECEPTORS
CN105658672A (zh)	2013-08-22	2016-06-08	阿塞勒隆制药公司	TGF-β受体II型变体及其用途
WO2016090035A2 (en)	2014-12-02	2016-06-09	La Jolla Institute For Allergy And Immunology	Modulators of activin and methods for modulating immune responses and t follicular helper cells
MA41919A (fr)	2015-04-06	2018-02-13	Acceleron Pharma Inc	Hétéromultimères alk4:actriib et leurs utilisations
BR112017021510A2 (pt)	2015-04-06	2018-07-03	Acceleron Pharma Inc	heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
JP6810702B2 (ja)	2015-04-06	2021-01-06	アクセルロンファーマインコーポレイテッド	シングルアームｉ型およびｉｉ型受容体融合タンパク質およびその使用
RS61881B1 (sr)	2015-04-22	2021-06-30	Biogen Ma Inc	Novi hibridni actriib proteini zamke za ligand za lečenje bolesti gubljenja mišića
WO2016205370A1 (en)	2015-06-15	2016-12-22	Santa Maria Biotherapeutics, Inc.	Methods of using activin receptor iib-based proteins
EP3344660B1 (en)	2015-08-31	2025-03-05	National Research Council of Canada	Tgf-beta-receptor ectodomain fusion molecules and uses thereof
EP3439741A4 (en)	2016-04-06	2020-05-06	Acceleron Pharma Inc.	ALK7 ANTAGONISTS AND USES THEREOF
AU2017293778B2 (en)	2016-07-07	2022-03-24	Acceleron Pharma Inc.	TGF-beta superfamily heteromultimers and uses thereof
WO2018009732A1 (en)	2016-07-08	2018-01-11	Regeneron Pharmaceuticals, Inc.	Anti-activin a antibodies and methods of use thereof for treating pulmonary arterial hypertension
EP3522913A4 (en)	2016-10-05	2020-10-28	Acceleron Pharma Inc.	ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES
JOP20190085A1 (ar)	2016-10-20	2019-04-17	Biogen Ma Inc	طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة

2016
- 2016-04-06 BR BR112017021510A patent/BR112017021510A2/pt not_active IP Right Cessation
- 2016-04-06 KR KR1020177031991A patent/KR20180002661A/ko not_active Ceased
- 2016-04-06 CN CN202210568634.1A patent/CN115073610A/zh active Pending
- 2016-04-06 JP JP2017552491A patent/JP7037363B2/ja not_active Expired - Fee Related
- 2016-04-06 DK DK16777229.2T patent/DK3280728T3/da active
- 2016-04-06 EA EA201792222A patent/EA037293B1/ru not_active IP Right Cessation
- 2016-04-06 WO PCT/US2016/000033 patent/WO2016164089A2/en not_active Ceased
- 2016-04-06 ES ES16777229T patent/ES2863564T3/es active Active
- 2016-04-06 EA EA202190016A patent/EA202190016A1/ru unknown
- 2016-04-06 CA CA2981737A patent/CA2981737A1/en active Pending
- 2016-04-06 MX MX2017012846A patent/MX391964B/es unknown
- 2016-04-06 MA MA054328A patent/MA54328A/fr unknown
- 2016-04-06 CN CN202210222650.5A patent/CN114736307A/zh active Pending
- 2016-04-06 CA CA2981833A patent/CA2981833A1/en active Pending
- 2016-04-06 EP EP21161146.2A patent/EP3889171B1/en active Active
- 2016-04-06 CN CN201680032890.1A patent/CN107847561B/zh not_active Expired - Fee Related
- 2016-04-06 US US15/092,609 patent/US10227393B2/en active Active
- 2016-04-06 EP EP25162196.7A patent/EP4599888A3/en active Pending
- 2016-04-06 MA MA041916A patent/MA41916A/fr unknown
- 2016-04-06 EP EP16777229.2A patent/EP3280728B1/en active Active
- 2016-04-06 KR KR1020177031989A patent/KR20180002659A/ko not_active Ceased
- 2016-04-06 WO PCT/US2016/026277 patent/WO2016164503A1/en not_active Ceased
- 2016-04-06 MA MA053400A patent/MA53400A/fr unknown
- 2016-04-06 EP EP20206064.6A patent/EP3828199B1/en active Active
- 2016-04-06 CN CN201680033093.5A patent/CN107709358A/zh active Pending
- 2016-04-06 HK HK18109788.7A patent/HK1250373A1/zh unknown
- 2016-04-06 MA MA41920A patent/MA41920B1/fr unknown
- 2016-04-06 US US15/092,577 patent/US10227392B2/en active Active
- 2016-04-06 AU AU2016244750A patent/AU2016244750B2/en not_active Ceased
- 2016-04-06 HK HK18112314.4A patent/HK1252957A1/zh unknown
- 2016-04-06 EP EP16777003.1A patent/EP3280435B1/en active Active
- 2016-04-06 JP JP2017552155A patent/JP7055636B2/ja active Active
- 2016-04-06 AU AU2016246708A patent/AU2016246708B2/en not_active Expired - Fee Related
2019
- 2019-01-18 US US16/251,325 patent/US10906958B2/en active Active
- 2019-01-18 US US16/251,935 patent/US11028145B2/en active Active
2020
- 2020-11-18 US US16/951,192 patent/US20220396607A1/en not_active Abandoned
- 2020-12-04 AU AU2020281136A patent/AU2020281136A1/en not_active Abandoned
2021
- 2021-01-27 AU AU2021200492A patent/AU2021200492A1/en not_active Abandoned
- 2021-04-15 JP JP2021069060A patent/JP7246618B2/ja active Active
- 2021-04-30 US US17/245,123 patent/US11827689B2/en active Active
2023
- 2023-08-21 US US18/236,082 patent/US20240158468A1/en active Pending

Also Published As

Publication number	Publication date
AU2016244750A1 (en)	2017-10-26
CN115073610A (zh)	2022-09-20
WO2016164089A2 (en)	2016-10-13
WO2016164089A3 (en)	2016-12-08
US20160297867A1 (en)	2016-10-13
JP2021104057A (ja)	2021-07-26
HK1248733A1 (zh)	2018-10-19
MA53400A (fr)	2021-08-04
US20220396607A1 (en)	2022-12-15
CN114736307A (zh)	2022-07-12
JP7037363B2 (ja)	2022-03-16
EP3828199B1 (en)	2025-10-15
US20190225669A1 (en)	2019-07-25
US20240158468A1 (en)	2024-05-16
AU2016244750B2 (en)	2021-02-18
EP3280435B1 (en)	2021-06-02
AU2016246708B2 (en)	2020-12-24
MA54328A (fr)	2021-10-06
EP3280435A2 (en)	2018-02-14
JP7055636B2 (ja)	2022-04-18
CA2981737A1 (en)	2016-10-13
US10227393B2 (en)	2019-03-12
EP4599888A2 (en)	2025-08-13
MA41920B1 (fr)	2021-05-31
JP2018513147A (ja)	2018-05-24
US10227392B2 (en)	2019-03-12
JP7246618B2 (ja)	2023-03-28
EP3280728A4 (en)	2018-09-12
EP3828199A1 (en)	2021-06-02
WO2016164503A1 (en)	2016-10-13
EA037293B1 (ru)	2021-03-05
AU2016246708A1 (en)	2017-10-26
EA202190016A1 (ru)	2021-08-31
EP3280728B1 (en)	2020-12-16
EP3280435A4 (en)	2018-12-19
CN107847561B (zh)	2022-03-29
US20220119491A1 (en)	2022-04-21
EP3889171A1 (en)	2021-10-06
MA41916A (fr)	2021-04-14
US20160298093A1 (en)	2016-10-13
AU2021200492A1 (en)	2021-02-25
US20190375820A1 (en)	2019-12-12
HK1252957A1 (zh)	2019-06-06
MA41920A (fr)	2018-02-14
KR20180002659A (ko)	2018-01-08
CN107847561A (zh)	2018-03-27
EP3280728A1 (en)	2018-02-14
EP3889171B1 (en)	2025-03-12
EP4599888A3 (en)	2025-10-29
HK1250373A1 (zh)	2018-12-14
US11827689B2 (en)	2023-11-28
ES2863564T3 (es)	2021-10-11
HK1248735A1 (zh)	2018-10-19
MX391964B (es)	2025-03-21
CA2981833A1 (en)	2016-10-13
US11028145B2 (en)	2021-06-08
EA201792222A1 (ru)	2018-04-30
CN107709358A (zh)	2018-02-16
AU2020281136A1 (en)	2021-01-07
KR20180002661A (ko)	2018-01-08
MX2017012846A (es)	2018-11-09
JP2018517399A (ja)	2018-07-05
US10906958B2 (en)	2021-02-02
BR112017021510A2 (pt)	2018-07-03

Publication	Publication Date	Title
DK3280728T3 (da)	2021-03-01	Alk7:actriib-heteromultimerer og anvendelser deraf
DK3303395T3 (da)	2020-01-27	Anti-cd40-antistoffer og anvendelser deraf
DK3274370T3 (da)	2020-02-17	Anti-ceacam6-antistoffer og anvendelser deraf
LT3280441T (lt)	2021-11-25	Anti-sortilino antikūnai ir jų naudojimo būdai
LT3258951T (lt)	2020-05-11	Anti-pvrig antikūnai ir jų panaudojimo būdai
DK3333191T3 (da)	2020-10-26	Anti-C10ORF54-antistoffer og anvendelser deraf
DK3247722T3 (da)	2023-01-30	Cytomegalovirusantigener og anvendelser deraf
DK3126388T3 (da)	2019-07-29	Anti-EGFRvIII-antistoffer og anvendelser deraf
DK3443009T3 (da)	2021-12-13	Anti-tim-3-antistoffer og sammensætninger
DK3337549T3 (da)	2019-09-16	Kateteranordninger med ventiler og tilhørende fremgangsmåder.
DK3988117T3 (da)	2025-01-20	Terapeutiske antistoffer og deres anvendelser
DK3157552T3 (da)	2020-01-13	Syntac-polypeptider og anvendelser deraf
DK3099172T3 (da)	2021-11-22	Modificeret biologisk bekæmpelsesmiddel og anvendelser deraf
EP3522913A4 (en)	2020-10-28	ALK4 HETEROMULTIMERS: ACTRIIB AND THEIR USES
DK3532499T3 (da)	2021-06-28	ANTI-IL-33-antistoffer og anvendelser deraf
LT3394065T (lt)	2021-06-25	Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai
DK3236991T3 (da)	2019-08-26	Fgf21-derivater og anvendelser deraf
DK3402821T5 (da)	2024-09-23	Psma-bindende antistof og anvendelser deraf
DK3209773T3 (da)	2020-06-15	Prolintolerante tripeptidylpeptidaser og anvendelser deraf
DK3161139T3 (da)	2020-10-19	Tlr-4-specifikke aptamerer og anvendelser heraf
EP3350489A4 (en)	2019-04-17	VALVE AND COUPLING
DK3359563T3 (da)	2019-09-30	Antigenreceptorer og anvendelser deraf
DK3128005T3 (da)	2021-06-28	Sirp-alfa-variantkonstruktioner og anvendelser deraf
DK3110447T3 (da)	2020-06-22	Anti-EGFR-antistof og anvendelser heraf
DK3337506T3 (da)	2021-09-06	Kombinationer og anvendelser deraf